A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical ...

Race Oncology has achieved a breakthrough with its lead drug candidate RC220, identifying for the first time the primary ...

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

Drug repurposing offers a promising and cost-effective strategy for developing new treatments. Metabolic ...

In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia ...

Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching between different mechanisms of action, while addressing access challenges ...

OVID reported positive phase 1 results for OV329, a next-generation GABA-AT inhibitor targeting drug-resistant focal onset ...

For patients with inflammatory bowel disease, antibiotics can be a double-edged sword. The broad-spectrum drugs often ...

Race Oncology (ASX:RAC) has announced the discovery of the primary mechanism of action of its lead anticancer candidate, (E,E ...

Researchers from McMaster University and MIT have discovered a new antibiotic to treat inflammatory bowel diseases (IBD).